What's Happening?
OneCyte and Kemp Proteins have formed a strategic partnership to improve cell line development for biopharmaceutical companies. This collaboration combines OneCyte's high-throughput single-cell analysis
platform with Kemp Proteins' machine learning-driven PROTiQ platform. The partnership aims to address challenges in cell line development, such as long development cycles and high failure rates, by integrating predictive in silico design with rapid experimental validation. This approach is expected to optimize amino acid sequences, assess developability risks, and identify elite clones with higher productivity, ultimately accelerating therapeutic development timelines.
Why It's Important?
The integration of machine learning and single-cell technology in cell line development could significantly enhance the efficiency and success rates of biopharmaceutical production. By reducing development time and improving yields, this partnership could expedite the delivery of new therapies to the market, benefiting patients and healthcare providers. The ability to quickly adapt to new therapeutic modalities is crucial in the rapidly evolving biopharmaceutical industry, and this collaboration positions both companies to meet these demands effectively.
What's Next?
The partnership will focus on refining the integrated workflow to further enhance its adaptability and efficiency. As the biopharmaceutical industry continues to evolve, the demand for innovative solutions in cell line development will grow. OneCyte and Kemp Proteins plan to expand their services to a global customer base, potentially setting new standards in the industry. Ongoing collaboration and innovation will be key to maintaining a competitive edge and meeting the needs of biopharma companies worldwide.
